Filing Flows › ADC Therapeutics SA (ADCT) › Q1 2026 › vs Q1 2025
ADC Therapeutics SA (ADCT) Q1 2026 vs Q1 2025 (year over year)
ADC Therapeutics SA's revenue fell $2.2M (-9%) from $23.0M in Q1 2025 to $20.9M in Q1 2026. The biggest changes: Product revenues, net +$2.6M (+15%); Royalties +$189K (+30%).
ADC Therapeutics SA, Q1 2026: revenue $20.9M (-10% year over year), operating margin -121.1%, net loss $33.0M, operating cash flow −$29.7M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Product revenues, net | $20.0M | $17.4M | $2.6M | +15% |
| Royalties | $818K | $629K | $189K | +30% |
| Revenue | $20.9M | $23.0M | −$2.2M | -9% |
| Net loss | $33.0M | $38.6M | −$5.6M | -15% |
| Costs & expenses | $53.8M | $61.6M | −$7.8M | -13% |
| Operating costs | $46.1M | $51.5M | −$5.4M | -10% |
| Interest & other, net | $7.7M | $10.0M | −$2.2M | -23% |
| Research & development | $19.9M | $28.9M | −$9.1M | -31% |
| Sales & marketing | $12.7M | $10.6M | $2.2M | +20% |
| General & admin | $9.9M | $10.0M | −$59K | -0.6% |
| Other operating costs | $3.6M | $2.1M | $1.6M | +75% |
| Operating cash sources | $33.0M | $38.3M | −$5.3M | -14% |
| Share-based compensation | $2.4M | $2.4M | $21K | +0.9% |
| Working capital & other | $816K | −$20.5M | $21.3M | — |
| Cash used in operations | $29.7M | $56.3M | −$26.6M | -47% |
| Net loss absorbed | $33.0M | $38.6M | −$5.6M | -15% |
Questions
How much did ADC Therapeutics SA's revenue grow year over year in Q1 2026?
ADC Therapeutics SA's revenue fell $2.2M (-9%) from $23.0M in Q1 2025 to $20.9M in Q1 2026.
What drove ADC Therapeutics SA's revenue change in Q1 2026?
Product revenues, net +$2.6M (+15%); Royalties +$189K (+30%).